EFFICACY OF TRANS-ARTERIAL RADIO EMBOLIZATION WITH YATTRIUM-90 FOR HEPATIC MALIGNANCIES

Objective: to assess the efficacy of trans-arterial radio embolization with yattrium-90 for end-stage unresectablehepato-cellular carcinoma HCC. Methods:End stage HCC patients who were treated with TARE between May 2019 and January 2023 at King Abdullah Medical City in Makkah, Saudi Arabia, were enrolled in this retrospective cohort study. TARE was performed with resin (SIR-Spheres®) loaded with Yttrium-90 microspheres (SIR-Spheres). 3 and 6 months after the completion of TARE, patients underwent a contrast-enhanced CT or MRI to evaluate their treatment responses, after which imaging follow-up was performed at 2- or 3-weeks intervals.All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS version 25.0 IBM, Armonk, NY, USA). Results:The study included 29 patients. Among them (65.5%) were Males. Interval decrease in size was found in (27.6%), Interval increase in size was observed in (24.1%). furthermore, the tumor was Stable in size in (48.3%).LR-TR Viable was found in (61.9%), LR-TR Nonviable was observed in (19%). Also LR-TR Equivocal was in (19%). Conclusion:TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy.